Chemotherapy Effects, Esophagus Cancer
Conditions
Keywords
Esophagus squamous carcinoma, First-line chemotherapy, Docetaxel, Cisplatin, 5-fluorouracil
Brief summary
This is a phase III clinical trial to compare the efficacy of docetaxel plus cisplatin versus 5-Fu plus cisplatin in the first line chemotherapy for advanced or metastatic esophageal squamous carcinoma patients.
Detailed description
Esophageal cancer is the 6th most common cause of cancer deaths worldwide and it is an endemic in many parts of the world, particularly in the developing countries, including China. Histologically, esophageal cancer can be classified as adenocarcinoma and esophageal squamous cell. carcinoma (ESCC) which is the most common histology in Asia. For locally advanced or metastatic ESCC patients, chemotherapy can improve overall survival (OS) and progression free survival (PFS). There is no standard first-line chemotherapy for ESCC patients. Cisplatin (DDP) plus fluorouracil is the most common used combination with a response rate of 25-35%. Previous studies showed that the combination of paclitaxel with cisplatin had good tolerance and efficacy to esophageal carcinoma. This is a prospective randomized control phase III clinical trial to compare the efficacy and safety between docetaxel/cisplatin and 5-Fu/cisplatin as the 1st line treatment in advanced or metastatic esophageal carcinoma patients. Sample size: This is a non-inferior study. The planned sample size was 358 patients, allowing for a 10% dropout rate and assuming the median progression free survival was 5.5 months in the experimental group and 4 months in the control group with a hazard ratio of 0.727, α=0.05, β=0.2. The planned enrolled time was 36 months and 12 months of follow up. The ratio between control and experimental group is 1:1.
Interventions
DRUGDocetaxel
60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
DRUGFluorouracil
5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
DRUGCisplatin
Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must give written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors. 2. Patients must have histologically confirmed esophageal squamous cell carcinoma without prior treatments including surgery, chemotherapy, radiotherapy, and targeting treatment. Patients were allowed to have palliative radiotherapy 3 months before the enrollment and the target lesions should not be within the radiotherapy region. The last date of adjuvant therapy should be over 6 months before the enrollment. 3. With measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. 4. With an expected life expectancy of ≥ 3 months. 5. With a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale. 6. Without serious system dysfunction and could tolerate chemotherapy. 7. Patients must have normal bone marrow function with a hemoglobin (HGB) of ≥90g/L, an white blood cell (WBC) counts of ≥4.0×10\^9/L，a neutrophil count of ≥2.0×10\^9/L, , a platelet count of ≥100×10\^9/L. 8. Patients must have normal liver and renal function with a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a creatinine (Cr) of ≤ 1.0 UNL, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL. 9. Patients must have normal electrocardiogram results and no history of congestive heart failure. 10. Women of childbearing age should voluntarily take contraceptive measures. Without drug addition 11. Patients must be with good compliance and agree to accept follow-up of disease progression and adverse events.
Exclusion criteria
1. Allergic to known drug 2. Patients who have received prior treatment including chemotherapy, radiotherapy and surgery for the advanced or metastatic diseases. 3. Receive docetaxel within 6 months as adjuvant or neoadjuvant chemotherapy. 4. Brain metastasis. 5. Without measurable or evaluable disease. 6. With history of other tumors except for those of cervical carcinoma in situ or skin basal cell carcinoma who had been completely treated and without relapse in last 5 years. 7. With serious diseases such as congestive heart failure, uncontrolled myocardial infarction and arrhythmia, liver failure and renal failure. 8. With neurological or psychiatric abnormalities that affect cognitive. 9. Pregnant or lactated women (premenopausal women must give urine pregnancy test before enrollment)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 36 months | From the date of randomization until the date of first documented relapse of disease or date of death from any cause, whichever came first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 36 months | From the date of randomization until the date of death from any cause. |
| Response rate | 36 months | Including complete response and partial response |
| Grade 3 and 4 toxicities | 36 months | According to the CTCAE |
| Quality of life--Score of the questionnaire | 36 months | EORTC QLQ-C30 and QLQ-OES18 questionnaire. |
Countries
China
Contacts
Primary ContactRui-Hua Xu, MD, PhD
Backup ContactMiao-Zhen Qiu, MD, PhD
Outcome results
None listed